Genprex, Inc. (GNPX) Stock Price & Analysis
Genprex, Inc. (GNPX) rose 4.27% to USD 7.81 as of July 25, 2026 at 15:05 UTC, according to Nexqual real-time market data.
GNPX last closed at USD 7.49; the session ranged USD 7.39–8.01 on volume of 12,815 shares. Market capitalization is $3.94M, with a 52-week range of USD 6.72–1,210 (NCM). Source: Nexqual, July 25, 2026 at 15:05 UTC.
Key Statistics (as of July 25, 2026 at 15:05 UTC)
| Price | USD 7.81 |
|---|---|
| Change | ▲ 4.27% (up) |
| Previous Close | USD 7.49 |
| Open | USD 7.57 |
| Day Range | USD 7.39 – 8.01 |
| 52-Week Range | USD 6.72 – 1,210 |
| Volume | 12,815 shares |
| Market Cap | $3.94M |
| Exchange | NCM |
Technical Analysis (GNPX)
Nexqual's technical model rates GNPX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 15:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.36 (neutral) |
| vs SMA50 | Below (USD 13.21) |
| MACD | -1.68 (negative) |
Analyst Ratings (GNPX)
Wall Street analysts rate GNPX "None", per Nexqual as of July 25, 2026 at 15:05 UTC.
| Consensus Rating | None |
|---|
Earnings (GNPX)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-03-31 | USD -286 vs est -451 ▲ beat |
| 2024-09-30 | USD -1,353 vs est -3,003 ▲ beat |
| 2024-06-30 | USD -3,300 vs est -2,530 ▼ miss |
Source: Nexqual, July 25, 2026 at 15:05 UTC.
Financials & Fundamentals (GNPX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -160.84% |
| Current Ratio | 5.61 |
| Total Cash | $18.05M |
| Total Debt | $0 |
| Free Cash Flow | $-9.10M |
Source: Nexqual, July 25, 2026 at 15:05 UTC.
Financial Health Score (GNPX)
Nexqual rates Genprex, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 15:05 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $18M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$14M |
| Efficiency | Critical — ROE -161%, ROA -76.2% |
Ownership (GNPX)
| Insider Ownership | +0.35% |
|---|---|
| Institutional Ownership | +0.71% |
| Shares Outstanding | 504,936 |
| Float | 480,214 |
| Short % of Float | +7.98% |
Source: Nexqual, July 25, 2026 at 15:05 UTC.
Leadership (GNPX)
Genprex, Inc. is led by Ryan M. Confer M.S. (age 43), President, CEO, CFO & Director, per Nexqual as of July 25, 2026 at 15:05 UTC.
| President, CEO, CFO & Director | Ryan M. Confer M.S. (age 43) |
|---|---|
| Senior Vice President of Human Resources | David M. Schloss |
| Senior Vice President of Intellectual Property & Licensing | Thomas C. Gallagher |
| Senior Vice President of Regulatory Affairs & Quality | Suzanne Thornton-Jones |
| Senior Director & Corporate Controller | Greg Jancarik C.M.A. |
Major Backers & Investors (GNPX)
Notable institutional backers of Genprex, Inc. include Fidelity, Mayflower Financial Advisors, LLC, according to Nexqual as of July 25, 2026 at 15:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.25% |
| Mayflower Financial Advisors, LLC | 0.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.3% |
Source: Nexqual, July 25, 2026 at 15:05 UTC.
From Genprex, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- In Type 2 diabetes, our technology is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin.   Oncology Platform   Our lead oncology drug candidate, REQORSA® Gene Therapy (generic name: quaratusugene ozeplasmid ), previously referred to as GPX-001, is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer ("NSCLC") and Small Cell Lung Cancer ("SCLC").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CODX | Co-Diagnostics, Inc. | USD 2.1 | ▼ 7.89% |
| DARE | Dare Bioscience, Inc. | USD 1.28 | ▲ 4.92% |
| AIM | AIM ImmunoTech Inc. | USD 0.25 | ▼ 0.4% |
| NNVC | NanoViricides, Inc. | USD 1.48 | ▼ 2.63% |
| AYTU | Aytu BioPharma, Inc. | USD 2.16 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:05 UTC. This page is informational and not investment advice.